Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||||
| DOI | 10.1016/J.GIM.2021.10.026 | ||||
| Año | 2022 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
Purpose: Monogenic disorders can present clinically heterogeneous symptoms. We hypothesized that in patients with a monogenic disorder caused by a large deletion, frequently additional loss-of-function (LOF)-intolerant genes are affected, potentially contributing to the phenotype. Methods: We investigated the LOF-intolerant gene distribution across the genome and its association with benign population and pathogenic classified deletions from individuals with presumably monogenic disorders. For people with presumably monogenic epilepsy, we compared Human Phenotype Ontology terms in people with large and small deletions. Results: We identified LOF-intolerant gene dense regions that were enriched for ClinVar and depleted for population copy number variants. Analysis of data from >143,000 individuals with a suspected monogenic disorder showed that 2.5% of haploinsufficiency disorder–associated deletions can affect at least 1 other LOF-intolerant gene. Focusing on epilepsy, we observed that 13.1% of pathogenic and likely pathogenic ClinVar deletions <3 megabase pair, covering the diagnostically most relevant genes, affected at least 1 additional LOF-intolerant gene. Those patients have potentially more complex phenotypes with increasing deletion size. Conclusion: We could systematically show that large deletions frequently affected admditional LOF-intolerant genes in addition to the established disease gene. Further research is needed to understand how additional potential disease-relevant genes influence monogenic disorders to improve clinical care and the efficacy of targeted therapies.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Stefanski, Arthur | Hombre |
Cleveland Clinic Foundation - Estados Unidos
CLEVELAND CLIN - Estados Unidos |
| 2 | Perez-Palma, Eduardo | Hombre |
Cleveland Clinic Foundation - Estados Unidos
Universidad del Desarrollo - Chile CLEVELAND CLIN - Estados Unidos |
| 3 | Mrdjen, Marko | Hombre |
Cleveland Clinic Foundation - Estados Unidos
CLEVELAND CLIN - Estados Unidos |
| 4 | McHugh, Megan | Mujer |
Cleveland Clinic Foundation - Estados Unidos
CLEVELAND CLIN - Estados Unidos |
| 5 | Leu, Costin | Hombre |
Cleveland Clinic Foundation - Estados Unidos
Broad Institute - Estados Unidos CLEVELAND CLIN - Estados Unidos Broad Inst MIT & Harvard - Estados Unidos |
| 6 | Lal, Dennis | Hombre |
Cleveland Clinic Foundation - Estados Unidos
Broad Institute - Estados Unidos Medizinische Fakultät - Alemania CLEVELAND CLIN - Estados Unidos Broad Inst MIT & Harvard - Estados Unidos Univ Cologne - Alemania |
| Fuente |
|---|
| National Institutes of Health |
| Bundesministerium für Bildung und Forschung |
| National Institute of Neurological Disorders and Stroke |
| Dravet Syndrome Foundation |
| Agradecimiento |
|---|
| This work was supported by the National Institute of Health (grants: NIH 5U54NS108874, 1R01NS112499-01A1), the Center Without Walls on ion channel function in epilepsy (Channelopathy-associated Research Center, grant U54 NS108874), German Federal Ministry for Education and Research (Bundesministerium f?r Bildung und Forschung, Treat-ION, 01GM1907D), and Dravet Syndrome Foundation research grant to D.L. Conceptualization: A.S. D.L.; Data Curation: A.S.; Formal Analysis: A.S. E.P.-P. M.M. M.M.H.; Investigation: A.S. E.P.-P. M.M. M.M.H.; Methodology: A.S. D.L.; Project Administration: A.S. D.L.; Supervision: D.L.; Visualization: A.S.; Writing-original draft: A.S. C.L. D.L.; Writing-review and editing: A.S. E.P.-P. M.M. M.M.H. C.L. D.L. This study contains previously published data by Truty et al.6 In their Ethics Declaration Truty et al6 declare ?data from genes unrelated to the presenting clinical phenotype were de-identified for analysis of baseline copy number variants under institutional review board approval (Western Institutional Review Board, 20161796).? |
| This work was supported by the National Institute of Health (grants: NIH 5U54NS108874, 1R01NS112499-01A1), the Center Without Walls on ion channel function in epilepsy (Channelopathy-associated Research Center, grant U54 NS108874), German Federal Ministry for Education and Research (Bundesministerium f?r Bildung und Forschung, Treat-ION, 01GM1907D), and Dravet Syndrome Foundation research grant to D.L. Conceptualization: A.S. D.L.; Data Curation: A.S.; Formal Analysis: A.S. E.P.-P. M.M. M.M.H.; Investigation: A.S. E.P.-P. M.M. M.M.H.; Methodology: A.S. D.L.; Project Administration: A.S. D.L.; Supervision: D.L.; Visualization: A.S.; Writing-original draft: A.S. C.L. D.L.; Writing-review and editing: A.S. E.P.-P. M.M. M.M.H. C.L. D.L. This study contains previously published data by Truty et al.6 In their Ethics Declaration Truty et al6 declare ?data from genes unrelated to the presenting clinical phenotype were de-identified for analysis of baseline copy number variants under institutional review board approval (Western Institutional Review Board, 20161796).? |